The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Computational extraction and analysis of de-identified medical records to characterize hyperammonemia in patients with fibrolamellar carcinoma (FLC).
 
Travis Zack
No Relationships to Disclose
 
Samantha Maisel
No Relationships to Disclose
 
Allison Frances O'Neill
No Relationships to Disclose
 
Michael P. La Quaglia
No Relationships to Disclose
 
Michael Herman
No Relationships to Disclose
 
Jennifer J. Knox
Honoraria - Novartis; Roche Canada
Consulting or Advisory Role - AstraZeneca/MedImmune; Lilly; Merck
Research Funding - AstraZeneca; Ipsen; Merck
Expert Testimony - AstraZeneca
 
Amin Yaqubie
No Relationships to Disclose
 
Alan P. Venook
Consulting or Advisory Role - Array BioPharma; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Genentech; Roche
 
Robert J. Mayer
Consulting or Advisory Role - Bayer
 
John Dozier Gordan
Consulting or Advisory Role - Genentech/Roche
Research Funding - ShangPharma Innovation (Inst)
Patents, Royalties, Other Intellectual Property - A small molecule patent has been submitted for a tool compound developed in my academic research, and is currently in provisional form. It has no current health applications but may eventually be developed into a clinically relevant compound. (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris